The first large-scale trials of two Ebola vaccines, GlaxoSmithKline's Chad3-EBO-Z and Merck and Newlink's rVSV-ZEBOV, has begun in Liberia at the Redemption Hospital in the capital Monrovia. The study, led by the US National Institutes of Health, was launched at the hospital on Sunday at an event attended by Liberian Vice-President Joseph Boaikai. The vaccines, which contain harmless elements of the deadly virus that trigger an immune response, were administered ...
via Medindia Health News
More READ 
Lake forest health and fitness http://ift.tt/1BRHnOx
No comments:
Post a Comment